1. Home
  2. ADNT vs HRMY Comparison

ADNT vs HRMY Comparison

Compare ADNT & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADNT
  • HRMY
  • Stock Information
  • Founded
  • ADNT 2016
  • HRMY 2017
  • Country
  • ADNT Ireland
  • HRMY United States
  • Employees
  • ADNT N/A
  • HRMY N/A
  • Industry
  • ADNT Auto Parts:O.E.M.
  • HRMY Biotechnology: Pharmaceutical Preparations
  • Sector
  • ADNT Consumer Discretionary
  • HRMY Health Care
  • Exchange
  • ADNT Nasdaq
  • HRMY Nasdaq
  • Market Cap
  • ADNT 1.9B
  • HRMY 2.0B
  • IPO Year
  • ADNT N/A
  • HRMY 2020
  • Fundamental
  • Price
  • ADNT $19.82
  • HRMY $33.08
  • Analyst Decision
  • ADNT Hold
  • HRMY Buy
  • Analyst Count
  • ADNT 9
  • HRMY 9
  • Target Price
  • ADNT $25.38
  • HRMY $47.00
  • AVG Volume (30 Days)
  • ADNT 761.2K
  • HRMY 1.1M
  • Earning Date
  • ADNT 11-08-2024
  • HRMY 10-29-2024
  • Dividend Yield
  • ADNT N/A
  • HRMY N/A
  • EPS Growth
  • ADNT N/A
  • HRMY N/A
  • EPS
  • ADNT 0.81
  • HRMY 2.11
  • Revenue
  • ADNT $14,855,000,000.00
  • HRMY $681,879,000.00
  • Revenue This Year
  • ADNT N/A
  • HRMY $24.37
  • Revenue Next Year
  • ADNT $1.14
  • HRMY $18.76
  • P/E Ratio
  • ADNT $24.13
  • HRMY $15.75
  • Revenue Growth
  • ADNT N/A
  • HRMY 25.83
  • 52 Week Low
  • ADNT $19.40
  • HRMY $22.89
  • 52 Week High
  • ADNT $37.19
  • HRMY $41.61
  • Technical
  • Relative Strength Index (RSI)
  • ADNT 37.20
  • HRMY 43.90
  • Support Level
  • ADNT $19.47
  • HRMY $31.02
  • Resistance Level
  • ADNT $21.62
  • HRMY $41.61
  • Average True Range (ATR)
  • ADNT 0.69
  • HRMY 1.69
  • MACD
  • ADNT -0.20
  • HRMY -0.13
  • Stochastic Oscillator
  • ADNT 8.80
  • HRMY 19.45

About ADNT Adient plc

Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment into this new company. Adient is the leading seating supplier to the industry with about one third of the global market. Its share in China is now nearly 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated seating revenue from joint ventures after factoring in the sale was about $3.8 billion in fiscal 2023 and consolidated China revenue was $1.4 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2023 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $15.4 billion and fiscal 2024 is forecast to about $14.6 billion.

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy.

Share on Social Networks: